[1]Park L, Jhaveri K, Cambron-Mellott MJ, et al. Perceptions and behaviors of US oncologists treating HR-positive HER2-negative metastatic breast cancer in second-line. 2024 SABCS. P5-01-08. [2]Turner NC, Oliveira M, Howell SJ, et al. CAPItello-291 Study Group. Capivasertib in Horm...
为了优化HR阳性、HER2阳性乳腺癌患者的疾病管理，未来的研究应该评估 (i) 在真实世界中，各种治疗和序贯联合内分泌治疗的疗效，包括一线抗HER2靶向治疗、化疗以及维持内分泌治疗的联合给药是否改善了HR阳性、HER2阳性MBC患者的结局；(ii) 内分泌治疗在HR低阳性肿瘤患者中的应用。参考文献：[1].Hammond ME, Hayes DF...
Our results indicate that BRCA2 mutations have no significant effect on the survival of Chinese women with HR-positive/HER2-negative breast cancer.Li, Pu-ChunZhu, Yi-FanPan, Jia-NiZhu, Qiao-YanLiao, Yu-YangDing, Xiao-WenZheng, Lin-Feng...
既往较为难治的HER2+和三阴性乳腺癌分型预后均得到显著改善。在新型药物不断发展和临床研究逐渐进步的情况下,临床实践中观察到HR+/HER2-早期乳腺癌与其他分型乳腺癌的预后差异逐渐缩小,其预后仍有很大的改善空间。 一方面,随着对HR+/HER2-乳腺癌复发风险的深入研究,此类患者的复发风险不容忽视。有研究显示约40%接...
[19]Xu BH, Ma F, Wang SS, et al. Sacituzumab Govitecan vs Treatment of Physician’s Choice in Asian Patients With Hormone Receptor–Positive and HER2–Negative Metastatic Breast Cancer: Results From the Phase 3 EVER-132-00...
[5] Mery B, Poulard C, Le Romancer M, Trédan O. Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. Int J Mol Sci. 2021;22(24):13512. [6] Ribas R, Pancholi S, Guest SK, et al. AKT Antagonist AZD5363 Influences Es...
phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAI...
2. PS14-03.Updated analyses from a Phase I study of the brain-penetrant oral SERD- SIM0270 in patients with ER-positive,HER2-negative advanced breast cancer. SABCS 2024. 3. PS14-04: SIM0270, a brain-penetrant o...
Increasingly mutant-targeted PI3K inhibitors, such as the investigational agent RLY-2608, may provide more potent efficacy in hormone receptor (HR)–positive, HER2-negative breast cancer, while decreasing the adverse effects (AEs) that are often associated with this class...
phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition(CDK 4/6i)in patients(pts)with unresectable or hormone receptor–positive(HR+),HER2-negative metastatic breast cancer(MBC):MAINTAIN trial.J ...